Clinical Practice, and Diagnosis and Treatment Strategies of Chronic Hepatitis D Virus (HDV)

Hepatitis is the liver inflammatory disease that gradually damages the liver. Hepatitis D/delta hepatitis is a liver infection caused by the hepatitis D virus (HDV). The HDV is a blood-borne pathogen and only occurs as either a co-infection with hepatitis B virus (HBV) or as a super-infection of persons with chronic HBV. It can be an acute for short-term infection or become a long-term chronic infection. In chronic infection HDV can cause serious liver damage (cirrhosis) and death at the end stage. The HDV infection is more common in Eastern Europe, South America, Africa, Central Asia, and the Middle East. At present no vaccine is available to prevent HDV. Vaccination against HBV provides the best prophylaxis against hepatitis D. The pegylated interferon alpha (Peg-IFNα) is the only therapy available to treat HDV infection that is associated with significant side-effects. Recently new medication bulevirtide, an HDV entry inhibitor, is approved to treat it. In this study, I have tried to discuss the virology, transmission, diagnosis, and treatment of the HDV infection.

Authors

Institutions

Publication Details

Journal
Innovation in Science and Technology
Published
2025-05-01
DOI
https://doi.org/10.63593/ist.2788-7030.2025.05.003
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Practice, and Diagnosis and Treatment Strategies of Chronic Hepatitis D Virus (HDV)

Haradhan Kumar Mohajan
Innovation in Science and Technology
Hepatitis C virus research
article

Clinical Practice, and Diagnosis and Treatment Strategies of Chronic Hepatitis D Virus (HDV)

Haradhan Kumar Mohajan
article en

Abstract

Hepatitis is the liver inflammatory disease that gradually damages the liver. Hepatitis D/delta hepatitis is a liver infection caused by the hepatitis D virus (HDV). The HDV is a blood-borne pathogen and only occurs as either a co-infection with hepatitis B virus (HBV) or as a super-infection of persons with chronic HBV. It can be an acute for short-term infection or become a long-term chronic infection. In chronic infection HDV can cause serious liver damage (cirrhosis) and death at the end stage. The HDV infection is more common in Eastern Europe, South America, Africa, Central Asia, and the Middle East. At present no vaccine is available to prevent HDV. Vaccination against HBV provides the best prophylaxis against hepatitis D. The pegylated interferon alpha (Peg-IFNα) is the only therapy available to treat HDV infection that is associated with significant side-effects. Recently new medication bulevirtide, an HDV entry inhibitor, is approved to treat it. In this study, I have tried to discuss the virology, transmission, diagnosis, and treatment of the HDV infection.

Innovation in Science and TechnologyVol. 4(4)
Premier University (BD), University of Chittagong (BD)
Openalex Percentile: Top 76%
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.